Tau-PET outcomes may thus permit more rapid assessment of pharmacodynamic effects and thereby facilitate early phase proof-of-concept trials.37 Furthermore, serial tau-PET measures could identify individuals at risk of rapid cognitive decline (Table 2; model 9). The gene discussed is MAPT; the disease is Mental deterioration.